Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis : Results of a Randomized Swedish Trial
(2016) In Arthritis Care and Research 68(12). p.1758-1766- Abstract
Objective To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) randomized to addition of infliximab or conventional combination treatment. Methods Multicentre, two-arm, parallel, randomized, active-controlled, open-label trial. RA patients with <1y symptom duration were recruited from 15 rheumatology clinics in Sweden between 2002-2005. Patients who did not achieve low disease activity after 3-4 months methotrexate therapy were randomized to addition of infliximab or conventional combination treatment with sulfasalazine+hydroxychloroquine. Yearly sick leave and disability pension days over 7 years after randomization were retrieved from nationwide registers kept by the Swedish Social Insurance... (More)
Objective To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) randomized to addition of infliximab or conventional combination treatment. Methods Multicentre, two-arm, parallel, randomized, active-controlled, open-label trial. RA patients with <1y symptom duration were recruited from 15 rheumatology clinics in Sweden between 2002-2005. Patients who did not achieve low disease activity after 3-4 months methotrexate therapy were randomized to addition of infliximab or conventional combination treatment with sulfasalazine+hydroxychloroquine. Yearly sick leave and disability pension days over 7 years after randomization were retrieved from nationwide registers kept by the Swedish Social Insurance Agency. Results Of 210 working age patients, 109 were randomized to infliximab (mean age=48.4y, 73% women) and 101 to conventional treatment (48.7y, 77%). The year before randomization the mean number of annual work days lost was 127 in the infliximab arm and 118 in the conventional treatment group (mean difference, 9; 95%CI, -23 to 39). Compared to the year before randomization, the mean changes at 7 years were -25 days in the infliximab and -26 days in the conventional treatment group (adjusted mean difference, 10; 95%CI, -25 to 46). The mean cumulative work loss days was 846 in the infliximab group and 701 in the conventional treatment group (adjusted mean difference, 104; 95%CI, -56 to 284). Conclusions Long-term work loss improved significantly in early RA randomized to infliximab+methotrexate or conventional combination therapy. No difference was detected between strategies, and the level of work loss days remained twice that observed in the general population.
TRIAL REGISTRATION NUMBER: NCT00764725 This article is protected by copyright. All rights reserved.
(Less)
- author
- Eriksson, Jonas K ; KARLSSON WALLMAN, JOHAN LU ; Miller, Heather ; Petersson, Ingemar F LU ; Ernestam, Sofia ; Vivar, Nancy ; van Vollenhoven, Ronald F and Neovius, Martin
- organization
- publishing date
- 2016-03-25
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Arthritis Care and Research
- volume
- 68
- issue
- 12
- pages
- 1758 - 1766
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:27015295
- scopus:84997079093
- wos:000393027400003
- ISSN
- 2151-4658
- DOI
- 10.1002/acr.22899
- language
- English
- LU publication?
- yes
- id
- a8338933-f4c4-4a53-a8e4-f69ed1e19339
- date added to LUP
- 2016-04-15 15:18:25
- date last changed
- 2024-11-01 18:00:57
@article{a8338933-f4c4-4a53-a8e4-f69ed1e19339,
abstract = {{<p>Objective To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) randomized to addition of infliximab or conventional combination treatment. Methods Multicentre, two-arm, parallel, randomized, active-controlled, open-label trial. RA patients with <1y symptom duration were recruited from 15 rheumatology clinics in Sweden between 2002-2005. Patients who did not achieve low disease activity after 3-4 months methotrexate therapy were randomized to addition of infliximab or conventional combination treatment with sulfasalazine+hydroxychloroquine. Yearly sick leave and disability pension days over 7 years after randomization were retrieved from nationwide registers kept by the Swedish Social Insurance Agency. Results Of 210 working age patients, 109 were randomized to infliximab (mean age=48.4y, 73% women) and 101 to conventional treatment (48.7y, 77%). The year before randomization the mean number of annual work days lost was 127 in the infliximab arm and 118 in the conventional treatment group (mean difference, 9; 95%CI, -23 to 39). Compared to the year before randomization, the mean changes at 7 years were -25 days in the infliximab and -26 days in the conventional treatment group (adjusted mean difference, 10; 95%CI, -25 to 46). The mean cumulative work loss days was 846 in the infliximab group and 701 in the conventional treatment group (adjusted mean difference, 104; 95%CI, -56 to 284). Conclusions Long-term work loss improved significantly in early RA randomized to infliximab+methotrexate or conventional combination therapy. No difference was detected between strategies, and the level of work loss days remained twice that observed in the general population.</p><p>TRIAL REGISTRATION NUMBER: NCT00764725 This article is protected by copyright. All rights reserved.</p>}},
author = {{Eriksson, Jonas K and KARLSSON WALLMAN, JOHAN and Miller, Heather and Petersson, Ingemar F and Ernestam, Sofia and Vivar, Nancy and van Vollenhoven, Ronald F and Neovius, Martin}},
issn = {{2151-4658}},
language = {{eng}},
month = {{03}},
number = {{12}},
pages = {{1758--1766}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Arthritis Care and Research}},
title = {{Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis : Results of a Randomized Swedish Trial}},
url = {{http://dx.doi.org/10.1002/acr.22899}},
doi = {{10.1002/acr.22899}},
volume = {{68}},
year = {{2016}},
}